Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RASolute 309: A Phase 3 registrational trial to evaluate the RAS(ON) inhibitor doublet combination of zoldonrasib plus daraxonrasib for pancreatic cancer

Next Previous
Trial Profile

RASolute 309: A Phase 3 registrational trial to evaluate the RAS(ON) inhibitor doublet combination of zoldonrasib plus daraxonrasib for pancreatic cancer

Status: Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 09 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daraxonrasib (Primary) ; Zoldonrasib (Primary)
  • Indications Adenocarcinoma; Pancreatic ductal carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms RASolute 309
  • Sponsors REVOLUTION Medicines

Most Recent Events

  • 09 Mar 2026 New trial record
  • 25 Feb 2026 According to Revolution Medicines media release, the trial is anticipated to be initiated in second half of 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top